Lexaria Bioscience is Revolutionizing Current Drug Delivery Platforms: CEO

Lexaria Bioscience Corp. (CSE:LXX) shares soared recently on news of a partnership with Altria Ventures to develop reduced-risk nicotine products

In this interview at the recent Cantech Investment Conference 2019 in Toronto, SmallCapPower spoke with Chris Bunka, Chairman and CEO of Lexaria Bioscience Corp. (CSE:LXX), about the Company’s DehydraTECH patented technology that masks the unwanted taste and improves speed of onset of drugs and molecules. Lexaria recently signed an agreement with Altria, a large nicotine company, who will assist in funding a research program to develop oral nicotine substitutes.

To read our full disclosure, please click on the button below: